56S1 Stock Overview Engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Sartorius Stedim Biotech S.A. Competitors Price History & Performance
Summary of share price highs, lows and changes for Sartorius Stedim Biotech Historical stock prices Current Share Price €186.20 52 Week High €280.50 52 Week Low €144.80 Beta 0.67 1 Month Change 10.21% 3 Month Change 3.33% 1 Year Change -22.16% 3 Year Change -59.00% 5 Year Change 27.01% Change since IPO 3,147.67%
Recent News & Updates
Sartorius Stedim Biotech S.A. to Report Fiscal Year 2024 Results on Jan 28, 2025 Nov 16
Third quarter 2024 earnings released: EPS: €0.26 (vs €0.28 in 3Q 2023) Oct 17
Second quarter 2024 earnings released: €0.011 loss per share (vs €1.44 profit in 2Q 2023) Jul 19
Now 22% overvalued Jun 07
Investor sentiment deteriorates as stock falls 16% Apr 25
First quarter 2024 earnings released: EPS: €0.58 (vs €1.21 in 1Q 2023) Apr 19 See more updates
Sartorius Stedim Biotech S.A. to Report Fiscal Year 2024 Results on Jan 28, 2025 Nov 16
Third quarter 2024 earnings released: EPS: €0.26 (vs €0.28 in 3Q 2023) Oct 17
Second quarter 2024 earnings released: €0.011 loss per share (vs €1.44 profit in 2Q 2023) Jul 19
Now 22% overvalued Jun 07
Investor sentiment deteriorates as stock falls 16% Apr 25
First quarter 2024 earnings released: EPS: €0.58 (vs €1.21 in 1Q 2023) Apr 19
Upcoming dividend of €0.69 per share Mar 26
Dividend of €0.69 announced Feb 19
New minor risk - Profit margin trend Feb 18
Sartorius Stedim Biotech S.A. has filed a Follow-on Equity Offering in the amount of €1.2 billion. Feb 08 Sartorius Stedim Biotech S.A. has filed a Follow-on Equity Offering in the amount of €1.2 billion. Sartorius Stedim Biotech S.A. to Report Nine Months, 2024 Results on Oct 17, 2024
Investor sentiment improves as stock rises 16% Dec 21
Investor sentiment improves as stock rises 16% Nov 07
Third quarter 2023 earnings released: EPS: €0.28 (vs €2.22 in 3Q 2022) Oct 20
Investor sentiment deteriorates as stock falls 17% Oct 16
New minor risk - Share price stability Aug 25
Second quarter 2023 earnings released: EPS: €1.44 (vs €2.33 in 2Q 2022) Jul 21
New minor risk - Share price stability Jun 29
Investor sentiment deteriorates as stock falls 16% Jun 22
First quarter 2023 earnings released: EPS: €1.21 (vs €2.93 in 1Q 2022) Apr 20
Upcoming dividend of €1.44 per share at 0.5% yield Mar 23
Full year 2022 earnings released: EPS: €9.51 (vs €4.50 in FY 2021) Feb 18 Sartorius Stedim Biotech S.A. Provides Earnings Guidance for the Fiscal Year 2023
Sartorius Stedim Biotech S.A. to Report Fiscal Year 2022 Results on Jan 26, 2023 Dec 22
Sartorius Stedim Biotech S.A., Annual General Meeting, Mar 27, 2023 Dec 08
Less than half of directors are independent Nov 16
Investor sentiment improved over the past week Nov 12
Third quarter 2022 earnings released: EPS: €2.22 (vs €1.60 in 3Q 2021) Oct 21
Sartorius Stedim Biotech S.A. Provides Earnings Guidance for the Fiscal Year 2022 Oct 19
Sartorius Stedim Biotech S.A. (ENXTPA:DIM) entered into a definitive agreement to acquire Albumedix Ltd. from private investors for approximately £420 million. Aug 10
Second quarter 2022 earnings released: EPS: €2.33 (vs €1.61 in 2Q 2021) Jul 23
First quarter 2022 earnings released: EPS: €2.93 (vs €1.24 in 1Q 2021) Apr 27
Less than half of directors are independent Apr 27
First quarter 2022 earnings released: EPS: €2.93 (vs €1.24 in 1Q 2021) Apr 22
Sartorius Stedim Biotech S.A. Confirms Earnings Guidance for the Year 2022 Apr 21
Sartorius Stedim Biotech S.A. Approves Dividend for the Fiscal Year 2021 Mar 30
Upcoming dividend of €1.26 per share Mar 21
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 20
Sartorius Stedim Biotech S.A. Updates Earnings Guidance for the Year 2022 Feb 18
Sartorius Stedim Biotech S.A. Recommends Dividend Feb 10
Sartorius Stedim Biotech S.A. (ENXTPA:DIM) completed the acquisition of chromatography equipment division from Novasep Holding SAS. Feb 08
Sartorius Stedim Biotech Provides Earnings Guidance for the Full Year 2022 Jan 27
Third quarter 2021 earnings released: EPS €1.60 (vs €1.10 in 3Q 2020) Oct 21
Second quarter 2021 earnings released: EPS €1.56 (vs €0.73 in 2Q 2020) Jul 22
Sartorius Stedim Biotech S.A. Raises Forecast for the Full Year 2021 Jul 07
First quarter 2021 earnings released: EPS €1.24 (vs €0.81 in 1Q 2020) Apr 24
Sartorius Stedim Biotech Raises Consolidated Sales Guidance for 2021 Apr 24
Sartorius Stedim Biotech Increases Earnings Guidance for 2021 Mar 19
Full year 2020 earnings released: EPS €3.88 (vs €2.54 in FY 2019) Feb 20
Revenue misses expectations Feb 20
New 90-day high: €416 Feb 18
New 90-day high: €366 Feb 03 Sartorius Stedim Biotech S.A. to Report Nine Months, 2021 Results on Oct 20, 2021
Sartorius Stedim Biotech S.A. (ENXTPA:DIM) signed an agreement to acquire chromatography equipment division from Novasep Holding SAS. Jan 08
Sartorius Stedim Biotech S.A. (ENXTPA:DIM) completed the acquisition of BIA Separations d.o.o. Nov 03
New 90-day high: €329 Oct 29
Third quarter earnings released Oct 21
Third-quarter earnings released: Revenue beats expectations Oct 21 Sartorius Stedim Biotech S.A. to Report Q1, 2021 Results on Apr 21, 2021
New 90-day high: €313 Oct 12
Sartorius Stedim Biotech S.A. (ENXTPA:DIM) entered into a definitive agreement to acquire BIA Separations d.o.o. for ?€360 million. Oct 03
New 90-day high - €303 Aug 25
New 90-day high - €273 Aug 07
Sartorius Aktiengesellschaft (XTRA:SRT) and Sartorius Stedim Biotech S.A. (ENXTPA:DIM) completed the acquisition of certain businesses from Danaher Corporation (NYSE:DHR). Jul 30
New 90-day high - €259 Jul 16 Shareholder Returns 56S1 DE Life Sciences DE Market 7D -2.6% -0.7% -1.4% 1Y -22.2% -3.9% 8.0%
See full shareholder returns
Return vs Market: 56S1 underperformed the German Market which returned 8.1% over the past year.
Price Volatility Is 56S1's price volatile compared to industry and market? 56S1 volatility 56S1 Average Weekly Movement 7.7% Life Sciences Industry Average Movement 7.2% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.9% 10% least volatile stocks in DE Market 2.5%
Stable Share Price: 56S1's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 56S1's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products.
Show more Sartorius Stedim Biotech S.A. Fundamentals Summary How do Sartorius Stedim Biotech's earnings and revenue compare to its market cap? 56S1 fundamental statistics Market cap €18.32b Earnings (TTM ) €160.60m Revenue (TTM ) €2.74b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 56S1 income statement (TTM ) Revenue €2.74b Cost of Revenue €1.55b Gross Profit €1.19b Other Expenses €1.02b Earnings €160.60m
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Jan 28, 2025
Earnings per share (EPS) 1.65 Gross Margin 43.33% Net Profit Margin 5.87% Debt/Equity Ratio 68.4%
How did 56S1 perform over the long term?
See historical performance and comparison Dividends
0.4% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/18 15:58 End of Day Share Price 2024/12/18 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Sartorius Stedim Biotech S.A. is covered by 31 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Stéphan Dubosq Arkeon Finance Charles Pitman-King Barclays Scott Bardo Berenberg
Show 28 more analysts 
